Evidence map›Paper›PMID 38332832›Full record

ArticleChemical science2024

How cycloalkane fusion enhances the cycloaddition reactivity of dibenzocyclooctynes.

Dennis Svatunek, Anton Murnauer, Zhuoting Tan, K N Houk, Kathrin Lang

Abstract read
In one paragraph

Article in Chemical science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Insights into Tetrazine-Benzene Cycloadditions.The journal of physical chemistry. A · 2026
    Article
  4. Article
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Dennis SvatunekDepartment of Chemistry and Biochemistry, University of California Los Angeles California 90095-1569 USA.ORCID https://orcid.org/0000-0003-1101-2376
Anton MurnauerDepartment of Chemistry and Applied Biosciences, ETH Zurich 8093 Zurich Switzerland kathrin.lang@org.chem.ethz.ch.
Zhuoting TanDepartment of Chemistry and Biochemistry, University of California Los Angeles California 90095-1569 USA.
K N HoukDepartment of Chemistry and Biochemistry, University of California Los Angeles California 90095-1569 USA.ORCID https://orcid.org/0000-0002-8387-5261
Kathrin LangDepartment of Chemistry and Applied Biosciences, ETH Zurich 8093 Zurich Switzerland kathrin.lang@org.chem.ethz.ch.ORCID https://orcid.org/0000-0002-1318-6567

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dibenzoannulated cyclooctynes have emerged as valuable compounds for bioorthogonal reactions. They are commonly used in combination with azides in strain-promoted 1,3-dipolar cycloadditions. They are typically, however, unreactive towards 3,6-disubstituted tetrazines in inverse electron-demand Diels-Alder cycloadditions. Recently a dibenzoannulated bicyclo[6.1.0]nonyne derivative (DMBO) with a cyclopropane fused to the cyclooctyne core was described, which showed surprising reactivity towards tetrazines. To elucidate the unusual reactivity of DMBO, we performed density functional theory calculations and revealed that a tub-like structure in the transition state results in a much lower activation barrier than in the absence of cyclopropane fusion. The same transition state geometry is found for different cycloalkanes fused to the cyclooctyne core albeit higher activation barriers are observed for increased ring sizes. This conformation is energetically unfavored for previously known dibenzoannulated cyclooctynes and allows tetrazines and azides to approach DMBO from the face rather than the edge, a trajectory that was hitherto not observed for this class of activated dieno- and dipolarophiles.

Identifiers

PMID38332832
PMCPMC10848739

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.